Quality of life (QoL) analyses from optimal (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1615-1622

  Chen, G ^a   Feng, J ^b   Zhou, C ^c   Wu, Y L ^d   Liu, X Q ^e   Wang, C ^f   Zhang, S ^g   Wang, J ^h   Zhou, S ^c   Ren, S ^c   Lu, S ⁱ   Zhang, L ^j,u   Hu, C P ^k   Hu, C ^l   Luo, Y ^m   Chen, L ⁿ   Ye, Ye ^o   Huang, J ^p   Zhi, X ^q   Zhang, Y ^r   Xiu, Q ^s   Ma, J ^t   You, C ^v   more..

^a HARBIN MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^f KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁱ SHANGHAI JIAO TONG UNIVERSITY   (China)

^j SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^k CENTRAL SOUTH UNIVERSITY   (China)

^l CENTRAL SOUTH UNIVERSITY   (China)

^m HUNAN CANCER HOSPITAL   (China)

ⁿ CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^o SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^p THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^q CAPITAL MEDICAL UNIVERSITY   (China)

^r ZHEJIANG CANCER HOSPITAL   (China)

^s SECOND MILITARY MEDICAL UNIVERSITY   (China)

^t Harbin Institute of Hematology and Oncology   (China)

^u PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^v SOUTHERN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Chemotherapy; EGFR mutations; Erlotinib; Non small cell lung cancer (NSCLC); Quality of life (QoL)

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EGFR GENE; EXON; FEMALE; GENE; GENE ACTIVATION; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 84878471164     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt012     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Molina JR, Yang P, Cassivi SD et al. Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
4. Suresh R, Chandra P. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 3(Suppl 1): 5-12.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer. http://www.nccn.org/ patients/patient_guidelines/nscl/index.html VERSION 1.2012 (18 February 2013, date last accessed).
6. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated nonsmall- cell lung cancer. N Engl J Med 2005; 353: 123-132.
7. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
8. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
9. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
10. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
11. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
12. Wu Y-L, Zhong WZ, Li LY et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007; 2: 430-439.
13. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
14. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831-3837.
15. Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
16. Mok T, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
17. Zhou SW, Ren SX, Yan LH et al. Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi 2008; 30: 469-472.
18. Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13 (13): 3913-3921.
19. Zhu YJ, Xia Y, Ren GJ et al. Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer. Chin Med J (Engl) 2010; 123(22): 3200-3205.